Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 22 (4), 463-475, 2021-04
Elsevier BV